Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis

English version České info

Background:
It has been suggested that outcomes of antidepressant treatment for major depressive disorder could be significantly improved if treatment choice is informed by genetic data. This study aims to test the hypothesis that common genetic variants can predict response to antidepressants in a clinically meaningful way.

Methods and Findings:
The NEWMEDS consortium, an academia–industry partnership, assembled a database of over 2,000 European-ancestry individuals with major depressive disorder, prospectively measured treatment outcomes with serotonin reuptake inhibiting or noradrenaline reuptake inhibiting antidepressants and available genetic samples from five studies (three randomized controlled trials, one part-randomized controlled trial, and one treatment cohort study). After quality control, a dataset of 1,790 individuals with high-quality genome-wide genotyping provided adequate power to test the hypotheses that antidepressant response or a clinically significant differential response to the two classes of antidepressants could be predicted from a single common genetic polymorphism. None of the more than half million genetic markers significantly predicted response to antidepressants overall, serotonin reuptake inhibitors, or noradrenaline reuptake inhibitors, or differential response to the two types of antidepressants (genome-wide significance p<5×10⁻⁸). No biological pathways were significantly overrepresented in the results. No significant associations (genome-wide significance p<5×10⁻⁸) were detected in a meta-analysis of NEWMEDS and another large sample (STAR*D), with 2,897 individuals in total. Polygenic scoring found no convergence among multiple associations in NEWMEDS and STAR*D.

Conclusions:
No single common genetic variant was associated with antidepressant response at a clinically relevant level in a European-ancestry cohort. Effects specific to particular antidepressant drugs could not be investigated in the current study.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. PLoS Med 9(10): e32767. doi:10.1371/journal.pmed.1001326
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001326

Souhrn

Zdroje

1. KesslerRC, ChiuWT, DemlerO, MerikangasKR, WaltersEE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617–627.

2. RushAJ, TrivediMH, WisniewskiSR, NierenbergAA, StewartJW, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905–1917.

3. TrivediMH, RushAJ, WisniewskiSR, NierenbergAA, WardenD, et al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28–40.

4. KatoM, SerrettiA (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15: 473–500.

5. KirchheinerJ, FuhrU, BrockmollerJ (2005) Pharmacogenetics-based therapeutic recommendations—ready for clinical practice? Nat Rev Drug Discov 4: 639–647.

6. MrazekDA, LermanC (2011) Facilitating clinical implementation of pharmacogenomics. JAMA 306: 304–305.

7. KimH, LimSW, KimS, KimJW, ChangYH, et al. (2006) Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 296: 1609–1618.

8. National Institute for Health and Clinical Excellence (2004) Depression: management of depression in primary and secondary care. London: National Institute for Health and Clinical Excellence.

9. UherR, TanseyKE, MalkiK, PerlisRH (2012) Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 13: 233–240.

10. SimonGE, PerlisRH (2010) Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 167: 1445–1455.

11. GarriockHA, KraftJB, ShynSI, PetersEJ, YokoyamaJS, et al. (2010) A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 67: 133–138.

12. IsingM, LucaeS, BinderEB, BetteckenT, UhrM, et al. (2009) A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66: 966–975.

13. HughesB (2009) Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nat Rev Drug Discov 8: 523–524.

14. UherR, Huezo-DiazP, PerroudN, SmithR, RietschelM, et al. (2009) Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9: 225–233.

15. ThomasL, MulliganJ, MasonV, TallonD, WilesN, et al. (2008) Genetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. Trials 9: 29.

16. PerroudN, BondolfiG, UherR, Gex-FabryM, AubryJM, et al. (2011) Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 12: 365–377.

17. UherR, PerroudN, NgMY, HauserJ, HenigsbergN, et al. (2010) Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 167: 555–564.

18. MalkiK, UherR, Paya-CanoJ, BinderE, RietschelM, et al. (2010) Convergent animal and human evidence suggests a role of PPM1A gene in response to antidepressants. Biol Psychiatry 69: 360–365.

19. PurcellS, NealeB, Todd-BrownK, ThomasL, FerreiraMA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.

20. Wittke-ThompsonJK, PluzhnikovA, CoxNJ (2005) Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 76: 967–986.

21. RoystonP, AltmanDG, SauerbreiW (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25: 127–141.

22. StreinerDL (2002) Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can J Psychiatry 47: 262–266.

23. UherR, MuthenB, SoueryD, MorsO, JaraczJ, et al. (2010) Trajectories of change in depression severity during treatment with antidepressants. Psychol Med 40: 1367–1377.

24. LeuchtS, KaneJM, EtschelE, KisslingW, HamannJ, et al. (2006) Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31: 2318–2325.

25. MontgomerySA, AsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.

26. HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.

27. BeckAT, WardCH, MendelsonM, MockJ, ErbaughJ (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571.

28. UherR, MaierW, HauserJ, MarusicA, SchmaelC, et al. (2009) Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 194: 252–259.

29. SkolAD, ScottLJ, AbecasisGR, BoehnkeM (2006) Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38: 209–213.

30. KallbergH, AlfredssonL, FeychtingM, AhlbomA (2010) Don't split your data. Eur J Epidemiol 25: 283–284.

31. DudbridgeF, GusnantoA (2008) Estimation of significance thresholds for genomewide association scans. Genet Epidemiol 32: 227–234.

32. HolmansP, GreenEK, PahwaJS, FerreiraMA, PurcellSM, et al. (2009) Gene ontology analysis of GWA study data sets provides insights into the biology of bipolar disorder. Am J Hum Genet 85: 13–24.

33. BrowningSR, BrowningBL (2007) Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet 81: 1084–1097.

34. PurcellSM, WrayNR, StoneJL, VisscherPM, O'DonovanMC, et al. (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460: 748–752.

35. HorstmannS, BinderEB (2009) Pharmacogenomics of antidepressant drugs. Pharmacol Ther 124: 57–73.